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Pancreatic adenocarcinoma, which is responsible for almost 5% of
all cancer related deaths in the Western world (Parker et al, 1996),
continues to be a major unresolved health problem. The large
majority of patients present with disease that is beyond the scope
of surgical cure, and their prognosis is extremely poor: in case of
distant metastases, the median survival duration is generally less
than 3 months (Schnall and Macdonald, 1996).
Single chemotherapeutic agents, as well as combination regi-
mens, have shown only modest activity in this fatal disease, with
response rates of the most active agents in the 10–20% range
(Warshaw and Fernandez-del Castillo, 1992). Recently, gemcita-
bine, a novel nucleoside analogue with preclinical activity against
a broad spectrum of solid tumours (Hertel et al, 1990), was evalu-
ated in a multicentre trial of 44 patients with advanced pancreatic
cancer (Casper et al, 1994). While only five objective responses
(11%) were documented, the investigators noted frequent subjec-
tive symptomatic benefit, often in the absence of an objective
response. In a subsequent randomized trial involving 126 pre-
viously untreated patients (Burris et al, 1997), gemcitabine was
compared with 5-fluorouracil (5-FU). Patients treated with
gemcitabine achieved modest but statistically significant improve-
ments in response rate and median survival compared with those
treated with 5-FU (5.6 vs 4.4 months). In addition, more clinically
meaningful effects on disease-related symptoms (pain control,
improvement in performance status and weight gain) were seen
with gemcitabine than with 5-FU (24% vs 5%). Similar clinically
beneficial effects were noted in patients who were treated with
gemcitabine after experiencing disease progression while
receiving 5-FU (Rothenberg et al, 1996). Although these recent
encouraging results with gemcitabine are a step in the right direc-
tion, better treatments for pancreatic cancer are certainly needed.
One possible approach to further improve therapeutic results
may represent the combination of gemcitabine with other active
cytotoxic drugs.
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Summary Although the novel cytidin analogue gemcitabine has shown superior anti-tumour activity than 5-fluorouracil in advanced
pancreatic cancer, further improvements of therapeutic results are warranted. This goal might be achieved by combining gemcitabine with
other active drugs. This trial evaluated the efficacy and tolerance of such a combination regimen with epirubicin and granulocyte colony-
stimulating factor (G-CSF) in patients with metastatic disease. Seventy patients with metastatic pancreatic adenocarcinoma were enrolled in
this multicentre trial. Patients received 4-weekly courses of a combination regimen consisting of epirubicin 60 mg m–2 given as intravenous
bolus injection on day 1, gemcitabine 1000 mg m–2 infused over 30 min on days 1, 8 and 15, and G-CSF administered at 5 mg kg–1 day–1
subcutaneously from days 2–6 during each cycle. The efficacy of treatment was assessed by conventional measures, i.e. objective response,
progression-free and overall survival, as well as by analysis of clinical benefit response (defined as ³ 50% reduction in pain intensity, ³ 50%
reduction in daily analgesic consumption, and/or ³ 20-point improvement in Karnofsky performance status that was sustained for ³ 4
consecutive weeks). Of 66 patients evaluable for objective response, one achieved complete and 13 partial remissions, for an overall
response rate of 21% (95% confidence interval (CI), 12–33%); 27 additional patients (41%) had stable and 25 (38%) increasing disease. The
median time to progression was 3.8 months. Median survival was 7.8 months, and the probability of surviving beyond 12 months was 21.2%.
Out of 60 patients with tumour-related symptoms, who were considered evaluable for clinical benefit response, 26 (43%) experienced
significant palliation. The median time to achieve a clinical benefit response was 7 weeks, and its median duration was 22 weeks.
Chemotherapy was well-tolerated with leukopenia/granulocytopenia representing the most common and dose-limiting side-effect.
Gastrointestinal and other subjective toxicities were infrequent and generally rated minor. We conclude that the combination of gemcitabine,
epirubicin and G-CSF seems to be an effective palliative treatment with only moderate toxic effects in patients with metastatic pancreatic
adenocarcinoma. Our results in terms of objective and clinical benefit response, as well as survival seem to suggest an advantage over
gemcitabine-monotherapy, though this remains to be confirmed in a randomized trial.
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anti-tumour activity of gemcitabine plus epirubicin in patients
with advanced pancreatic cancer. The latter drug was chosen
because of its documented activity in this disease (Wils et al, 1985;
Kornek et al, 1995), and its potential drug synergism without (non-
haematologic) cross toxicity (Lueftner et al, 1996; Garcia-Conde
et al, 1997). To allow administration of adequate drug doses of
both gemcitabine and epirubicin, and to prevent/counteract myelo-
suppression that was assumed to represent the dose-limiting toxi-
city (Lueftner et al, 1996), granulocyte colony-stimulating factor
(G-CSF) using a convenient and cost-effective 5-day administra-
tion schedule was routinely used (Ribas et al, 1996). The objective
of our trial was to determine the anti-tumour efficacy and tolerance
of this combination regimen in patients with metastatic pancreatic
adenocarcinoma. The former was assessed by conventional
measures, i.e. objective response, time to progression and median
survival, as well as by clinical benefit response analysis as pre-
viously described (Rothenberg et al, 1996; Burris et al, 1997).
PATIENTS AND METHODS
Patient selection
To be entered in this trial, all patients were required to have histo-
logically or cytologically ascertained metastatic adenocarcinoma
of the pancreas. Patients with resectable tumours as well as those
with locally advanced, inoperable disease were not included in the
study. All patients were required to have bidimensionally measur-
able disease, to be 75 years of age or younger, and to have an
anticipated life expectancy of al least 3 months. Furthermore,
patients were required to have a baseline Karnofsky performance
status of at least 50, and to have adequate renal (serum creatinine
level < 1.5 mg dl–1), liver (total bilirubin level < 1.5 mg dl –1 and
transaminase levels less than two times the upper limits of normal)
and bone marrow function (leucocyte count ³ 4000 ml–1, absolute
granulocyte count ³ 2000 ml–1 and platelet count ³ 100 000 ml–1).
In addition, all patients had to have normal pretreatment electro-
cardiograms (ECG) and echocardiograms (left ventricular ejection
fraction of more than 50% and no wall motion abnormalities).
Patients with a history of cardiovascular disease, any other serious
or uncontrolled concurrent medical illness or with central nervous
system metastases were not eligible for treatment, as were those
who had undergone any prior palliative chemotherapy or radio-
therapy. A minimum of 2 weeks was required to have elapsed in
case of prior abdominal exploration or palliative surgery. Informed
consent was obtained from all patients according to institutional
regulations.
Pretreatment and follow-up evaluation
Pretreatment evaluation included a complete medical history,
physical examination, ECG, echocardiography and routine labora-
tory studies. The latter consisted of a complete blood count (CBC)
with platelet and leucocyte differential count, and an 18-function
biochemical profile. Imaging procedured included chest X-ray and
computerized tomography of the abdomen. CBCs, differential
counts and liver functional parameters were determined weekly,
and complete biochemical profiles were assessed before each
treatment cycle. Objective tumour assessments were performed at
the end of every two cycles during chemotherapy and every 3
months after discontinuation of treatment. Echocardiography was
repeated every 8–12 weeks during therapy.
Treatment protocol
Chemotherapy consisted of epirubicin 60 mg m–2 given as an intra-
venous (i.v.) bolus injection on day 1, gemcitabine 1000 mg m–2
diluted in normal saline and administered i.v. over 30 min on days
1, 8 and 15, plus G-CSF administered at 5 mg kg–1 day–1 subcuta-
neously from days 2–6 during each cycle. Treatment courses were
repeated every 4 weeks, and continued in patients achieving objec-
tive response or stable disease until a total of six courses.
Concomitant medications routinely administered before cytotoxic
drug administration included 8 mg ondansetron plus 8 mg dexa-
methasone (the latter given only on day 1).
Toxicity and dosage modification guidelines
Adverse reactions were evaluated according to World Health
Organization (WHO) criteria (Milleret al, 1981). Chemo-
therapeutic drug doses were reduced by 25% in subsequent cycles
if the lowest WBC (absolute granulocyte) count was less than
1000 ml–1 (500 ml–1), the lowest platelet count was less than
50 000 ml–1, or if any severe (³ WHO grade 3) nonhaematologic
toxicity was observed in the previous cycle. Treatment could be
delayed for up to 2 weeks if the WBC count was lower than
3000 ml–1 and/or the platelet count lower than 75 000 ml–1;
prolonged administration of G-CSF was recommended in the
former group of patients. Any patient who required more than
2 weeks for haematologic recovery was taken off the study.
Assessment of objective and clinical benefit response
The primary efficacy end point was response rate. A complete
response (CR) was defined as the disappearance of all clinical
evidence of tumour for a minimum of 4 weeks during which time
the patient was free of all symptoms related to cancer. Partial
response (PR) was defined as a >50% decrease in the sum of the
products of the longest perpendicular diameters of all measurable
disease with no new lesions appearing and none progressing for at
least 4 consecutive weeks. Patients were rated progressive (PD) if
any new lesion appeared, or tumour size increased by 25% over
pretreatment measurements, or in case of a deterioration in clinical
status that was consistent with disease progression. Patients who
failed to meet the criteria of CR, PR, or PD and who remained on
study for at least 2 months were classified as having stable disease
(SD). Two objective measurements that showed a response at at
least 4-week intervals were required to confirm a patients’
response; all tumour measurements in patients who responded
were reviewed and confirmed by a reference radiologist.
Secondary efficacy endpoints included the duration of response
(measured from the onset of the best response to the date of
disease progression), time to progression (TTP; calculated from
the date of initiation of therapy to the date when progressive
disease was first observed) and overall survival.
In addition to these ‘objective study end-points’, clinical benefit
was evaluated in symptomatic patients as previously described
(Rothenberg et al, 1996; Burris et al, 1997). Pain (computed as the
mean of the pain intensity scores recorded daily by the patient on a
100 mm VAS, plus analgesic consumption (expressed as morphine
equivalent mg per day) computed as the mean of the daily use indi-
cated in a diary) and karnofsky performance status (assessed
weekly by two independent observers with selection of the lower
value if the scores differed) comprised the primary measures of
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recorded weekly (and excluding patients who developed third-
space fluid or required parenteral nutrition at any time during the
study) was considered a secondary measure. To achieve an overall
rating of positive clinical benefit response, patients had to be posi-
tive for at least one parameter (pain: a ³ 50% improvement in pain
intensity and/or a ³ 50% decrease in analgesic consumption
compared to baseline; Karnofsky performance status: a ³ 20-point
improvement over baseline; weight: increase by ³ 7% over base-
line) without being negative for any of the others (i.e. deterioration
in pain intensity measurements and/or increase in analgesic
consumption by any degree; worsening in performance status
by  ³ 20 points over baseline). This improvement had to last for ³ 4
weeks. The primary measures of pain and performance status were
evaluated first; a patient who was rated stable on these primary
measures (i.e. categorized neither as positive or as negative) could
be classified as having achieved an overall clinical benefit
response only if weight was positive. All other patients were
classified as not having achieved clinical benefit response.
The duration of clinical benefit response was defined as the
duration of the positive classification in case of a single com-
ponent. If multiple components were positive, the duration of
clinical benefit response was defined as the largest number of
consecutive weeks during which there was a positive change for
at least one of the components.
Statistical methods
Using standard statistical methods, a two-stage design was
employed in the protocol (Gehan, 1961). If no CR or PR were
noted in the first 14 patients, a response rate of > 20% could be
excluded with 95% confidence and accrual would stop. If at least
one CR or PR was observed, > 30 patients were to be entered in the
study to determine the response rate more accurately. For the
response rates, 95% confidence intervals (CI) were calculated as
previously described (Anderson et al, 1982). The distribution of
TTP and time to death from the date of study entry were estimated
using the Kaplan–Meier product-limit method (Kaplan and Meier,
1958).
RESULTS
Patient population
Between November 1995 and March 1997, a total of 70 patients
were entered onto this trial from five different institutions. Only
four patients were ineligible by study criteria. One had a history of
cardiac impairment, two had inadequate baseline documentation
of measurable disease, and one had acinar cell instead of adenocar-
cinoma histology. All other patients were considered evaluable for
response and toxicity assessment. The demographic data, prior
surgical procedures, histological grade and sites of metastatic
tumour of the 66 eligible patients are listed in Table 1. There were
39 men and 27 women, with a median age of 62 years. Fourteen
had undergone prior potential curative surgery with disease
recurrence after a median of 10 months (range 3–76). Fifteen
patients had palliative bypass surgery for biliary and/or gastric
decompression, and eight patients had received endoscopic
stents for relieving obstructive jaundice before study entry. The
large majority of patients had multiple intra-abdominal sites
of metastases, and all except six patients were suffering from
disease-related symptoms: 51 of the 60 symptomatic patients
(85%) had pain at study entry, 32 of whom (63%) had a baseline
pain intensity score greater than 20 points, and 46 (90%) required
more than 10 morphine-equivalent mg day–1 for control of pain.
Similarly, most patients had an impaired performance status at
study entry (91%), and 48 (73%) had experienced weight loss,
ranging from 5% to 37% of premorbid body weight.
Treatment summary
A total of 271 cycles were administered to the 66 patients with a
median of 4 cycles per patient (range 1–6). The median duration of
treatment was 128 days, with a range of 28–168 days. Treatment
was stopped because of toxic side-effects in only one patient, two
warranted early discontinuation for other, personal reasons, and in
all other patients therapy was stopped because of progression,
including six patients with tumour complications while still
receiving chemotherapy, who required palliative endoscopic or
surgical intervention (four biliary and two intestinal obstructions).
There were no major protocol violations.
Objective response and survival
Response, time to progression and survival data are summarized in
Table 2. The overall response rate was 21% for all 66 eligible
patients (95% CI 12–33%), including one CR and 13 PR. The
median time to response was 2.7 months (range 1.8–4), and the
median duration of response was 7.5 months (range 3–22). An
additional 27 patients (41%) showed stabilization of disease
lasting for a median of 5.8 months (range 3–13.5) and in 25
patients (38%) tumour progression could not be abrogated by
chemotherapy.
At the time of this analysis, all patients had experienced
progressive disease. Fifty-seven patients (86.4%) have died, and
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Table 1 Pretreatment characteristics
Characteristic No. of patients (%)
Number of patients entered/eligible 70/66
Sex
Male 39 (59)
Female 27 (41)
Median age in years (range) 62 (32–75)
Karnofsky performance status
90–100 6 (9)
70–80 33 (50)
50–60 27 (41)
Prior surgery
None 26 (39)
Explorative laparotomy 11 (17)
Palliative bypass 15 (23)
Whipple or left resection 14 (21)
Histological grade
G1 4 (6)
G2 40 (61)
G3 22 (33)
Sites of metastases
Liver 46 (70)
Abdominopelvic mass 60 (91)
Lung 5 (8)
Extraabd.lymph nodes/soft-tissue 4 (6)
Bone 3 (5)
Adrenals 2 (3)the median follow-up duration of the nine patients still alive is
12 months. The median time to progression was 3.8 months (range
1.5–23). Median survival was 7.8 months (range 1.8–28+), and
the probability of surviving beyond 12 months was 21.2%.
Clinical benefit response
Sixty patients with tumour-related symptoms (pain and/or
impaired performance status ± weight-loss) were considered
evaluable for clinical benefit response. In 15/51 patients suffering
from pain at study entry, pain intensity and/or analgesic use was
reduced compared to baseline values, and 30 were classified as
stable in this category (including 8/9 patients without pain at entry,
but ³ 1 other specific cancer-related symptom). Improvement in
pain with no worsening of performance status occurred in nine
patients, whereas both pain and performance status improved in
six. An additional ten patients had an improvement in performance
status while being rated stable in the pain category. Therefore a
total of 25 patients were classified as clinical benefit responders by
primary measures. With regard to weight gain, the secondary
measure of clinical benefit, eight patients had a positive change
(> 7% increase from baseline). Seven of these patients had already
improved in one of the primary measures, and one was considered
stable in pain and performance status. According to this case, the
total number of primarily symptomatic patients experiencing a
clinical benefit response with gemcitabine + epirubicin + G-CSF
increased to 26 (43.3%). The median time to achieve a clinical
benefit response was 7 weeks, and the median duration of clinical
benefit was 22 weeks.
Toxicity
All 66 patients, who received a total of 271 cycles of therapy (813
administrations of gemcitabine), were assessable for toxicity.
Side-effects associated with treatment are listed in Table 3. The
dose-limiting toxicity was myelosuppression. Leukopenia
occurred in 57 patients (86%), and was grade 3 or 4 in 22 patients
(33%). The median nadir WBC count was 3430 ml–1 (range
500–25 900 ml–1). The time to WBC count recovery to more than
3000 ml –1 was short, i.e. 96% of episodes of leukopenia resolved
within 7 days. The variations in granulocyte counts paralleled
those of WBCs, and the median nadir count was 1759 ml–1 (range
60–10 130 ml–1). Thrombocytopenia was noted in a total of 35
patients (53%), and was grade 3 or 4 in seven and four patients
respectively. There were no episodes of bleeding. The median
nadir platelet count was 122 000 ml–1 (range 9000–968 000 ml–1)
with no evidence of a cumulative nature of this side-effect. Only
four patients (6%) developed grade 3/4 anaemia requiring RBC
transfusion, whereas mild anaemia was recorded in 48 patients
(73%). The median nadir of haemoglobin was 10.6 g dl–1 (range
5.4–13.7 g dl–1). Eleven patients developed documented infection,
and two of them required hospitalization for granulocytopenic
sepsis, both of whom were treated successfully.
Minor treatment-related elevations in liver functional parame-
ters were noted in fewer than one-third of the patients, and did not
result in any dose modifications or discontinuation from treatment.
Apart from hair loss in 79% (total alopecia 23%), gastro-
intestinal toxicities were the most frequently encountered non-
haematologic side-effects: nausea/vomiting occurred in 32%,
though symptoms were generally mild, confined to the day of drug
administration, and responsive to standard anti-emetic therapy.
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Table 2 Summary of treatment results (n = 66)
Complete response 1 (1.5%)
Partial response 13 (20%)
Stable disease 27 (41%)
Progression 25 (38%)
Overall response rate 14/66 (21%)
95% confidence interval 12%–33%
Time to progression (months)
Median 3.8
Range 1.5–23.0
Overall survival (months)
Median 7.8
Range 1.5–28.0+
1-year survival rate 21%
Table 3 Summary of maximum treatment-associated toxicities (n = 66)
Toxicity Number of patients/WHO toxicity grade (%)
123 4
Haematological and other laboratory-based toxicity
Leukopenia 17 (26) 18 (27) 19 (29) 3 (5)
Granulocytopenia 13 (20) 15 (23) 19 (29) 9 (14)
Thrombocytopenia 15 (23) 9 (14) 7 (11) 4 (6)
Anaemia 22 (33) 26 (39) 3 (5) 1 (2)
Bilirubin 4 (6) 2 (3) – –
Alkaline phosphatase 15 (23) 6 (9) 1 (2) –
Serum transaminases 14 (21) 8 (12) 2 (3) –
Symptomatic toxicity
Nausea/vomiting 15 (23) 4 (6) –
Stomatitis 3 (5) 5 (8) – –
Diarrhoea 4 (6) 2 (3) – –
Constipation 3 (5) 4 (6) 2 (3) –
Infection 5 (8) 4 (6) 2 (3) –
Fever 5 (8) 2 (3) – –
Alopecia 14 (21) 23 (35) 15 (23) –
Cutaneous 7 (11) 3 (5) – –
Phlebitis 3 (5) 2 (3) – –Stomatitis was recorded in eight patients, and diarrhoea or consti-
pation occurred in six and seven patients respectively. Uncommon
non-myelosuppressive toxicities included minor (grade 1 or 2)
skin rash (15%) that was treated symptomatically with topical
corticosteroids and/or systemic antihistamines, fever in the
absence of infection (11%), chemically-induced phlebitis (8%),
peripheral neuropathy (3%) and G-CSF-related myalgias/arthral-
gias and/or fever in 3%.
Twenty patients (30%) had at least one treatment delay of 1
week at some time during therapy, and the total of delayed courses
was 32 (12%). The reasons for delayed courses were haematologic
in 16 and non-haematologic in five, including protracted stom-
atitis, intercurrent infection, port-a-cath-implantation, palliative
surgery and personal reasons in one patient each.
Eighteen patients (27%) had a 25% dose reduction of cytotoxic
drugs during treatment according to the study protocol, because of
severe haematologic (n = 13) or other systemic toxicities (n = 2),
or both (n = 3). Only one patient discontinued therapy because of
toxicity (protracted thrombocytopenia for > 2 weeks), and there
were no toxic deaths. Overall, there was no evidence for cumula-
tive toxicity, since both treatment delays and requirements for dose
reductions were not more common during late cycles.
DISCUSSION
Although in a randomized trial the novel cytidin analogue gem-
citabine was shown to be more effective than 5-FU in advanced
pancreatic cancer, the reported objective response rate was only
5.4%, there was only a modest survival advantage (5.65 vs 4.41
months), and only one out of four patients (23.8%) experienced
clinical benefit (Burris et al, 1997). Further improvements are
certainly warranted, and might be achieved by combining gemcit-
abine with other active cytotoxic drugs. Encouraging preliminary
data in patients with this common malignancy have been reported
very recently for its combination with cisplatin (Heinemann et al,
1997), as well as bolus (Cascinu et al, 1998) and continuous
infusion 5-FU (Cortes-Funes et al, 1998). Epirubicin is another
classical agent that has shown to be active for the treatment of
advanced pancreatic cancer with a different mode of action and a
toxicity profile that is distinct from that of gemcitabine (Wils et al,
1985; Kornek et al, 1995). A phase I/II combination study with
this anthracycline using 1000 mg m–2 of gemcitabine and
20 mg m–2 of epirubicin on days 1, 8 and 15 of a 28-day cycle that
has been performed in patients with advanced breast cancer, has
demonstrated feasibility, potential synergistic activity and accept-
able tolerance with neutropenia constituting the dose-limiting toxi-
city (Lueftner et al, 1996). The aim of the present study was to
determine the anti-tumour activity of a comparable drug dose
regimen in advanced pancreatic adenocarcinoma, though the entire
dose of the anthracycline was given on day 1, followed by a short,
i.e. a 5-day course of the haematopoetic growth factor G-CSF in
order to counteract/minimize myelosuppression.
In this study we obtained a 21% overall remission rate (95% CI,
12–33%) in 66 evaluable patients and a median response duration
of 7.5 months. With an additional 41% of patients experiencing
stable disease (for a median duration of 5.8 months),
chemotherapy with gemcitabine, epirubicin and G-CSF resulted in
abrogation of progression of this aggressive tumour in almost two-
thirds. These objective response data are even more interesting
considering the fact that all of our patients had metastatic disease,
as opposed to most other studies in pancreatic cancer that have
also included patients with only advanced locoregional disease,
who are known to have a much better prognosis (Warshaw and
Fernandez-del Castillo, 1992; Andre et al, 1996). Keeping this in
mind, the most striking results of our study are the median time of
progression-free (3.8 months) and overall survival (7.8 months), as
well as the frequent palliative effects obtained: clinically signifi-
cant and sustained improvements in pain, analgesic consumption
and/or Karnofsky performance score were observed in 43% of
symptomatic patients, which in agreement with the objective
results of treatment, is almost a doubling of the rate of clinical
benefit responders reported for gemcitabine alone (using the same
rigorous definitions). The onset of clinical benefit (7 weeks) was
equally rapid as reported by Burris et al (1997) and its duration
was 22 weeks. It seems noteworthy that the beneficial effects of
gemcitabine + epirubicin + G-CSF were not negated by more
frequent or severe clinically relevant treatment-related toxicities.
Although grade 3 and 4 neutropenia was more commonly
observed than in the gemcitabine trial with previously untreated
patients (43% vs 23%), it was rarely associated with serious infec-
tions, a finding that is likely to be related to the prophylactic use of
a haematopoetic growth factor. Thrombocytopenia was also more
pronounced with the combination regimen, but again there were
no (bleeding) complications and/or requirement for platelet substi-
tution. As it concerns the frequency and degree of non-haemato-
logic adverse reactions, except for alopecia the addition of
epirubicin to gemcitabine did not seem to result in an increase
when compared to historical data of gemcitabine monotherapy.
The even lower rate of severe gastrointestinal toxicities (< 5% in
the present trial) might be explained by routine concomitant
administration of a serotonin antagonist with chemotherapy (plus
additional corticosteroids on the day of epirubicin).
In conclusion, the combination of gemcitabine + epirubicin +
G-CSF seems to be an effective palliative therapy for non-
pretreated advanced pancreatic cancer accompanied by acceptable
toxicity. Although objective and clinical benefit response as well
as survival data suggest a possible advantage over gemcitabine
monotherapy, results will have to be confirmed in a randomized
trial.
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